PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference
LA JOLLA, Calif. , Sept. 11, 2020 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics to Present at the 2020 Wells Fargo Virtual Healthcare Conference
LA JOLLA, Calif. , Sept. 3, 2020 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements
LA JOLLA, Calif. , Aug. 31, 2020 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that pursuant to an amendment of its term loan agreement with Oxford LLC ,
View HTML
Toggle Summary Regulus Therapeutics Reports Second Quarter 2020 Financial Results and Recent Updates
Completion of Dosing in Phase 1 Multiple Ascending Dose Study ("MAD") of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease ("ADPKD")   FDA Orphan Designation of RGLS4326 for ADPKD   Appointment of Denis Drygin, Ph.D., as Chief Scientific Officer LA JOLLA, Calif. , Aug.
View HTML
Toggle Summary Regulus Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
LA JOLLA, Calif. , Aug. 6, 2020 /PRNewswire/ -- Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan , President and Chief Executive Officer of
View HTML
Toggle Summary Regulus Therapeutics Appoints Denis Drygin, Ph.D., as Chief Scientific Officer
LA JOLLA, Calif. , Aug. 3, 2020 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Denis Drygin , Ph.D., as
View HTML
Toggle Summary Regulus Therapeutics Announces FDA Orphan Drug Designation of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
LA JOLLA, Calif. , July 29, 2020 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the U.S.
View HTML
Toggle Summary Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
LA JOLLA, Calif. , July 22, 2020 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the completion of dosing for the Phase 1
View HTML
Toggle Summary Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates
Initiated Third and Final Cohort of the Multiple Ascending Dose Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease LA JOLLA, Calif. , May 14, 2020 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and
View HTML
Toggle Summary Regulus Reports Fourth Quarter and Year-End 2019 Financial Results and Recent Updates
FDA Removal of Partial Clinical Hold for Phase I Multiple Ascending Dose Study of RGLS4326 Reinitiated Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD Closed $26 Million Second Tranche of Private Financing LA JOLLA, Calif. , March 12, 2020 /PRNewswire/ --  Regulus Therapeutics
View HTML